Neumora Therapeutics, Inc. filed a Form 8-K with the SEC on August 14, 2026, disclosing a leadership transition at the chief executive level and announcing financial results for the second quarter ended June 30, 2026.

Key Highlights

  • CEO transition effective August 14, 2026: Joshua Pinto, Ph.D., the company's current President, succeeded Paul L. Berns as Chief Executive Officer on that date.
  • New Executive Chairperson: Paul L. Berns will assume the role of Executive Chairperson of the Board of Directors following the transition.
  • Dual role retained: Dr. Pinto will continue to serve as President in addition to his new role as CEO, according to the filing.
  • Board appointment: The Board approved Dr. Pinto's appointment as a Class III director, effective August 14, 2026, with a term expiring at the 2029 Annual Meeting of Stockholders.
  • Board approval date: The Leadership Transition and Dr. Pinto's director appointment were both approved by the Board on August 12, 2026.
  • Q2 2026 results announced: The company announced financial results for the second quarter ended June 30, 2026, with the full text furnished as Exhibit 99.1.

Neumora Therapeutics Leadership Transition and Q2 2026 Financial Disclosure

According to the filing, Neumora Therapeutics, Inc. (NASDAQ:NMRA), headquartered at 260 Arsenal Place, Suite 1, Watertown, Massachusetts 02472, reported two significant developments on August 14, 2026. The company disclosed a planned leadership transition in which Joshua Pinto, Ph.D., formerly serving as President, assumed the title of Chief Executive Officer. Paul L. Berns, the outgoing CEO, moved into the role of Executive Chairperson of the Board of Directors. The filing states the transition became effective on August 14, 2026, referred to in the filing as the "Transition Date."

The Board's approval of the Leadership Transition occurred on August 12, 2026, two days before the effective date, the filing noted. In connection with that approval, the Board also appointed Dr. Pinto as a Class III director, effective as of the Transition Date. The filing states his director term is set to expire at the 2029 Annual Meeting of Stockholders, and he will serve until his successor is elected and qualified or until his earlier death, resignation, or removal. The filing references Dr. Pinto's prior business experience as having been described in the company's Definitive Proxy Statement on Schedule 14A filed on April 17, 2026.

Separately, the filing disclosed under Item 2.02 that Neumora announced financial results for the second quarter ended June 30, 2026. The filing states that the full text of the related press release is furnished as Exhibit 99.1. The filing notes that information furnished under Item 2.02, including Exhibit 99.1, "shall not be deemed to be 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934." The 8-K was signed by Michael Milligan, Chief Financial Officer, on August 14, 2026.

What Was Disclosed

Neumora Therapeutics disclosed a CEO succession effective August 14, 2026, with Joshua Pinto, Ph.D. becoming CEO and Paul L. Berns becoming Executive Chairperson, alongside the announcement of second quarter 2026 financial results furnished as an exhibit.